Geron Corporation (Nasdaq:GERN) today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases – Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with ... read more

Geron Corporation; Amicus Therapeutics; Complete Genomics, Inc.; Archemix Corp.; Neomend, Inc.; and TOPICA Pharmaceuticals, Inc. made the following tribute to Alexander Barkas: ... read more

Geron Corporation (Nasdaq: GERN) today announced that, effective immediately, the Company will focus on its first-in-class oncology programs. As a consequence, the Company will discontinue further ... read more

Geron Corporation (Nasdaq: GERN) today reported financial results for the three and nine months ended September 30, 2011. For the third ... read more

Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2011 on Thursday, November 3, 2011, after the closing of the equity market. ... read more

Geron Corporation (Nasdaq: GERN) today announced data on the use of GRNOPC1, oligodendrocyte progenitors derived from human embryonic stem cells, for myelin repair in a non-human primate model. ... read more

Geron Corporation (Nasdaq: GERN) today announced two presentations on the company’s ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal ... read more

Geron Corporation (NASDAQ:GERN) announced today that its board of directors has appointed John A. Scarlett, M.D. as its Chief Executive Officer and to its board of directors. Geron ... read more

Geron Corporation (Nasdaq: GERN) today announced that management will present a company overview at two upcoming investor conferences. ... read more